Literature DB >> 26245638

Outcome of second- and third-line Helicobacter pylori eradication therapies based on antimicrobial susceptibility testing.

Sarah Draeger1, Nicole Wüppenhorst1, Manfred Kist1, Erik-Oliver Glocker2.   

Abstract

OBJECTIVES: The objective of this study was to assess the outcome of antimicrobial susceptibility-guided therapies in Helicobacter pylori-infected individuals who had undergone unsuccessful prior eradication treatments.
METHODS: From October 2004 to December 2013, 481 H. pylori-positive patients with prior unsuccessful eradication treatments were administered susceptibility-guided salvage eradication treatments. Six months on, treatment outcome was assessed by urea breath test, stool antigen ELISA, Helicobacter urease test or microbiology and/or histopathology.
RESULTS: Resistance to metronidazole and clarithromycin was high in patients with prior unsuccessful eradication treatments and was dependent on the number of treatment failures. Susceptibility-guided salvage eradication treatments achieved eradication rates of nearly 70% in these patients. No particular regimen was significantly better than another.
CONCLUSIONS: Antimicrobial susceptibility testing prevents prescription of inefficient antimicrobials and enables individualized and promising salvage treatments in patients with prior unsuccessful eradication treatments.
© The Author 2015. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26245638     DOI: 10.1093/jac/dkv223

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  4 in total

1.  Empirical vs. Susceptibility-Guided Treatment of Helicobacter pylori Infection: A Systematic Review and Meta-Analysis.

Authors:  Olga P Nyssen; Marta Espada; Javier P Gisbert
Journal:  Front Microbiol       Date:  2022-06-14       Impact factor: 6.064

2.  Efficacy and safety of sequential versus quadruple therapy as second-line treatment for helicobacter pylori infection-A randomized controlled trial.

Authors:  Daniela Munteanu; Ohad Etzion; Gil Ben-Yakov; Daniel Halperin; Leslie Eidelman; Doron Schwartz; Victor Novack; Naim Abufreha; Pavel Krugliak; Alexander Rozenthal; Nava Gaspar; Alexander Moshkalo; Vitaly Dizingof; Alexander Fich
Journal:  PLoS One       Date:  2017-09-28       Impact factor: 3.240

Review 3.  Importance of antimicrobial susceptibility testing for the management of eradication in Helicobacter pylori infection.

Authors:  Nazlı Arslan; Özlem Yılmaz; Ebru Demiray-Gürbüz
Journal:  World J Gastroenterol       Date:  2017-04-28       Impact factor: 5.742

4.  Susceptibility-guided therapy for Helicobacter pylori infection treatment failures.

Authors:  Lou Yu; Laisheng Luo; Xiaohua Long; Xiao Liang; Yingjie Ji; Qi Chen; Yanyan Song; Xiaobo Li; David Y Graham; Hong Lu
Journal:  Therap Adv Gastroenterol       Date:  2019-09-09       Impact factor: 4.409

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.